190 related articles for article (PubMed ID: 25724369)
1. Quantitative urinary proteomics using stable isotope labelling by peptide dimethylation in patients with prostate cancer.
Li C; Zang T; Wrobel K; Huang JT; Nabi G
Anal Bioanal Chem; 2015 May; 407(12):3393-404. PubMed ID: 25724369
[TBL] [Abstract][Full Text] [Related]
2. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma.
Miyamoto KK; McSherry SA; Robins SP; Besterman JM; Mohler JL
J Urol; 1994 Apr; 151(4):909-13. PubMed ID: 7510346
[TBL] [Abstract][Full Text] [Related]
3. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
Tsoi TH; Chan CF; Chan WL; Chiu KF; Wong WT; Ng CF; Wong KL
PLoS One; 2016; 11(9):e0162217. PubMed ID: 27598335
[TBL] [Abstract][Full Text] [Related]
4. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
5. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer.
Takeuchi S; Arai K; Saitoh H; Yoshida K; Miura M
J Urol; 1996 Nov; 156(5):1691-5. PubMed ID: 8863572
[TBL] [Abstract][Full Text] [Related]
6. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer.
Ikeda I; Miura T; Kondo I
Br J Urol; 1996 Jan; 77(1):102-6. PubMed ID: 8653278
[TBL] [Abstract][Full Text] [Related]
7. The C-terminal fragment of prostate-specific antigen, a 2331 Da peptide, as a new urinary pathognomonic biomarker candidate for diagnosing prostate cancer.
Nakayama K; Inoue T; Sekiya S; Terada N; Miyazaki Y; Goto T; Kajihara S; Kawabata S; Iwamoto S; Ikawa K; Oosaga J; Tsuji H; Tanaka K; Ogawa O
PLoS One; 2014; 9(9):e107234. PubMed ID: 25233230
[TBL] [Abstract][Full Text] [Related]
8. Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis.
Wymenga LF; Groenier K; Schuurman J; Boomsma JH; Elferink RO; Mensink HJ
BJU Int; 2001 Aug; 88(3):231-5. PubMed ID: 11488735
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel candidate urinary protein biomarkers for prostate cancer in a multiethnic cohort of South African patients via label-free mass spectrometry.
Adeola HA; Soares NC; Paccez JD; Kaestner L; Blackburn JM; Zerbini LF
Proteomics Clin Appl; 2015 Jun; 9(5-6):597-609. PubMed ID: 25708745
[TBL] [Abstract][Full Text] [Related]
10. GC/MS-based metabolomic approach to validate the role of urinary sarcosine and target biomarkers for human prostate cancer by microwave-assisted derivatization.
Wu H; Liu T; Ma C; Xue R; Deng C; Zeng H; Shen X
Anal Bioanal Chem; 2011 Aug; 401(2):635-46. PubMed ID: 21626193
[TBL] [Abstract][Full Text] [Related]
11. Furan and p-xylene as candidate biomarkers for prostate cancer.
Jiménez-Pacheco A; Salinero-Bachiller M; Iribar MC; López-Luque A; Miján-Ortiz JL; Peinado JM
Urol Oncol; 2018 May; 36(5):243.e21-243.e27. PubMed ID: 29395956
[TBL] [Abstract][Full Text] [Related]
12. Screening, identification of prostate cancer urinary biomarkers and verification of important spots.
Zhao H; Zhao X; Lei T; Zhang M
Invest New Drugs; 2019 Oct; 37(5):935-947. PubMed ID: 30610587
[TBL] [Abstract][Full Text] [Related]
13. Determination of amino acids in urine of patients with prostate cancer and benign prostate growth.
Sroka WD; Boughton BA; Reddy P; Roessner U; Słupski P; Jarzemski P; Dąbrowska A; Markuszewski MJ; Marszałł MP
Eur J Cancer Prev; 2017 Mar; 26(2):131-134. PubMed ID: 27222937
[TBL] [Abstract][Full Text] [Related]
14. Identification of the metabolic signatures of prostate cancer by mass spectrometry-based plasma and urine metabolomics analysis.
Yu C; Niu L; Li L; Li T; Duan L; He Z; Zhao Y; Zou L; Wu X; Luo C
Prostate; 2021 Dec; 81(16):1320-1328. PubMed ID: 34590739
[TBL] [Abstract][Full Text] [Related]
15. Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer.
Sequeiros T; Rigau M; Chiva C; Montes M; Garcia-Grau I; Garcia M; Diaz S; Celma A; Bijnsdorp I; Campos A; Di Mauro P; Borrós S; Reventós J; Doll A; Paciucci R; Pegtel M; de Torres I; Sabidó E; Morote J; Olivan M
Oncotarget; 2017 Jan; 8(3):4960-4976. PubMed ID: 27903962
[TBL] [Abstract][Full Text] [Related]
16. Expression of PCA3 and PSA genes as a biomarker for differential diagnosis of nodular hyperplasia and prostate cancer.
Coelho FF; Guimarães FL; Cabral WL; Salles PG; Mateo EC; Nogueira e Nogueira LM; Fonseca CE; Gomes KB
Genet Mol Res; 2015 Oct; 14(4):13519-31. PubMed ID: 26535666
[TBL] [Abstract][Full Text] [Related]
17. Seminal plasma as a source of prostate cancer peptide biomarker candidates for detection of indolent and advanced disease.
Neuhaus J; Schiffer E; von Wilcke P; Bauer HW; Leung H; Siwy J; Ulrici W; Paasch U; Horn LC; Stolzenburg JU
PLoS One; 2013; 8(6):e67514. PubMed ID: 23826311
[TBL] [Abstract][Full Text] [Related]
18. Molecular Diagnostic of Prostate Cancer From Body Fluids Using Methylation-Specific PCR (MS-PCR) Method.
Minciu R; Dumache R; Gheorghe P; Daminescu L; Rogobete AF; Ionescu D
Clin Lab; 2016; 62(6):1183-6. PubMed ID: 27468582
[TBL] [Abstract][Full Text] [Related]
19. Urinary microRNA-based signature improves accuracy of detection of clinically relevant prostate cancer within the prostate-specific antigen grey zone.
Salido-Guadarrama AI; Morales-Montor JG; Rangel-Escareño C; Langley E; Peralta-Zaragoza O; Cruz Colin JL; Rodriguez-Dorantes M
Mol Med Rep; 2016 Jun; 13(6):4549-60. PubMed ID: 27081843
[TBL] [Abstract][Full Text] [Related]
20. Sequential changes of urinary pyridinoline and deoxypyridinoline as markers of metastatic bone tumor in patients with prostate cancer: a preliminary study.
Samma S; Kagebayashi Y; Yasukawa M; Fukui Y; Ozono S; Hirao Y; Sato H; Okajima E
Jpn J Clin Oncol; 1997 Feb; 27(1):26-30. PubMed ID: 9070337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
